Long-term safety and real-world effectiveness of fingolimod in relapsing multiple sclerosis

Abstract

Charlotte Druart, Souraya El Sankari, Vincent van Pesch Neurology Department, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium Abstract: With a growing number of disease-modifying therapies becoming available for relapsing multiple sclerosis, there is an important need to gather real-world evidence data regarding long-term treatment effectiveness and safety in unselected patient populations. Although not providing as high a level of evidence as randomized controlled trials, and prone to bias, real-world studies from observational studies or registries nevertheless provide crucial information on real-world outcomes of a given therapy. In addition, evaluation of treatment satisfaction and impact on quality of life are increasingly regarded as complementary outcome measures. Fingolimod was the first oral disease-modifying therapy approved for relapsing multiple sclerosis. This review aims to summarize current knowledge on the long-term effectiveness and safety outcomes of multiple sclerosis patients on fingolimod. Impact on treatment satisfaction and quality of life will be discussed according to available data. Keywords: multiple sclerosis, fingolimod, quality of life, safety, effectiveness, long-term, real-world evidence, patient-reported outcomes

Keywords

• Multiple Sclerosis
• fingolimod
• quality of life
• safety
• effectiveness
• long-term
• real-world evidence
• patient-reported outcomes